BPC-157: what the research literature actually shows
A neutral summary of what has (and hasn't) been established about BPC-157 in in-vitro and animal research studies — no dosing, no claims, just the science.
BPC-157 (Body Protection Compound-157) is one of the most-studied peptides in the research literature and also one of the most misrepresented on the consumer internet. This article summarizes what the research record actually establishes, in-vitro and in animal models, and where genuine uncertainty remains. It does not describe human use, dosing, or clinical outcomes — those questions are outside the scope of research-use-only material.
What BPC-157 is
BPC-157 is a synthetic 15-amino-acid peptide derived from a fragment of a larger protein originally isolated from human gastric juice. Sequence:
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
- Molecular formula: C62H98N16O22
- Molecular weight: ~1419 Da
- CAS number: 137525-51-0
- Common form: lyophilized white powder, reconstituted in bacteriostatic water for laboratory work
The research base
Most of the published BPC-157 literature comes from a single research group at the University of Zagreb (Croatia), led by Predrag Sikirić. Over 100 peer-reviewed papers have been published, primarily in rodent models. Key mechanisms proposed in the literature include:
- Modulation of nitric oxide (NO) synthesis pathways
- Interaction with the vascular endothelial growth factor (VEGF) axis
- Effects on gap-junction communication in gastric epithelium
- Modulation of dopaminergic and serotonergic systems in animal models
These are proposed mechanisms in animal studies, not established human pharmacology.
What has and hasn't been established
| Established (in-vitro / animal) | Not established | |---|---| | Stable in gastric acid (does not degrade like most peptides) | Human pharmacokinetics | | Bioavailable when administered orally in rodents | Human efficacy for any condition | | Effects on wound healing in rat models | Safe long-term human dosing | | Effects on tendon-bone healing in rat models | Regulatory approval anywhere for human use |
Regulatory status
BPC-157 has no marketing authorization from any major regulator (FDA, EMA, PMDA, COFEPRIS) as of 2026. In September 2023 the FDA placed BPC-157 on its 503A/503B "difficult to compound" list, effectively prohibiting compounding pharmacies from preparing it. It is not on the WADA prohibited list by name, but it falls under S0 (non-approved substances) for athletes in competition.
For laboratory research, BPC-157 is available as Research Use Only (RUO) reference material — the same regulatory category as thousands of other unapproved compounds studied in pharmacology labs.
Why researchers request it
The most common in-vitro applications documented in supplier records are:
- Reference standard for HPLC/LC-MS assay development
- Comparator compound in wound-healing screens using cultured fibroblasts
- Positive control for angiogenesis assays (tube formation, chick chorioallantoic membrane)
- Structure-activity relationship (SAR) studies of gastric-protective peptides
Storage and handling for laboratory work
Standard for lyophilized peptides:
- Store lyophilized powder at -20°C desiccated
- Once reconstituted, aliquot and freeze at -80°C for long-term storage
- Working solutions are stable at 2–8°C for approximately 7–14 days depending on buffer
- Avoid repeated freeze-thaw cycles — divide into single-use aliquots
The bottom line
BPC-157 is a real research compound with a real (if narrow) peer-reviewed base in rodent models. It is not an approved therapy, and any claim that positions it as one is outside the research literature. If you're sourcing it for reference or in-vitro work, insist on batch-specific COAs, mass-spec identity confirmation, and cold-chain shipping — the standards you'd apply to any research reagent.
For our current batch documentation, see BPC-157 in the catalog. Every vial ships with the lot's Janoshik report already available in the COA Library.